Detalhe da pesquisa
1.
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Future Oncol
; 19(9): 631-642, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083373
2.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Blood
; 134(23): 2036-2045, 2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511239
3.
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
Br J Cancer
; 122(8): 1158-1165, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32147671
4.
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Blood
; 125(18): 2771-8, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25766724